Keyuan Pharmaceutical Keyuan Pharmaceutical

Stock Code: 301281
Confirm
Investor Relations

Investor Relations Management System

Investor Relations Activity Record

IPO announcement

Company Profile

1

Shandong Keyuan Pharmaceutical Co., Ltd. (Stock Code: 301281.SZ), established in 2004, is a leading domestic enterprise in the chemical raw material medicine segment. Its products cover key disease areas such as diabetes, anesthesia, cardiovascular, and mental health.

The company focuses on the research, development, production, and sales of chemical raw materials and their preparations. All products have passed the national GMP certification, and core products have successively passed official drug administration certifications from multiple countries, including the European EDQM, the US FDA, Japan PMDA, and Korea MFDS. After successfully listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a high-speed development stage driven by both digital intelligence and capital, with its business spanning dozens of countries and regions globally.

In the continuous process of capitalizing and internationalizing, the company leverages its unique advantages of integrated raw material and preparation, and auxiliary material and preparation, to cultivate the chronic disease field. It implements a strategy of maintaining technological leadership through R&D, maintaining reputation through quality systems, and promoting development through customer satisfaction. It is making efforts in both domestic and international markets, continuously shaping new advantages for the company's development.

The company adheres to technological innovation to drive industrial upgrading, making innovative breakthroughs in technology R&D, digital manufacturing, and quality control. It has established long-term and stable cooperative relationships with R&D companies and universities such as Shanghai WuXi AppTec, Beijing Sunshine Novo, Beijing Nuokangda, Chongqing Boten Pharmaceutical, Tianjin Kairuiying Pharmaceutical, and Shandong University. It focuses on addressing industrial technological needs, promoting the transformation and application of scientific and technological achievements, continuously improving the company's technological innovation capabilities and market competitiveness, and achieving high-quality development.

With its cutting-edge technological innovation, R&D capabilities, and robust quality control capabilities, Keyuan Pharmaceutical has obtained numerous industry-leading patents and has been awarded numerous honors, including Shandong High-tech Enterprise, Shandong Enterprise Technology Center, Shandong Gazelle Enterprise, Shandong Specialized and New Small and Medium-sized Enterprise, Jinan Key Laboratory, Jinan Proton Pump Inhibitor Engineering Laboratory, and Jinan Expert Workstation, continuously forging a strong engine for the company's development.

Shandong LINO Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Keyuan Pharmaceutical, focusing on chemical pharmaceutical preparations. With the mission of "guarding life and health with digital medicine," the company continuously strengthens its "one body, two wings, three pillars" development strategy. Relying on the three pillars of technological R&D, digital manufacturing, and cultural marketing, it implements digital operation, digital service, and digital customer acquisition, continuing the bloodline of "Healthy China, sincere commitment," and creating a Chinese innovative brand in digital medicine.

In the future, Keyuan Pharmaceutical, together with LINO Pharmaceutical, will continue to focus on the chronic disease field, expand other characteristic market segments, establish a presence domestically, and continuously improve its overseas market layout. It aims to build a pharmaceutical enterprise with international competitiveness, enhance its brand awareness and influence, and continuously contribute to the global life and health cause!